• Publications
  • Influence
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. TheExpand
  • 387
  • 38
  • PDF
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
A large body of evidence, including longitudinal analyses of personality change, suggests that core personality traits are predominantly stable after age 30. To our knowledge, no study hasExpand
  • 383
  • 33
  • PDF
An algorithm for identifying nonsystematic delay-discounting data.
  • M. Johnson, W. Bickel
  • Psychology, Medicine
  • Experimental and clinical psychopharmacology
  • 1 June 2008
Several [corrected] discounting studies have use the R2 measure to identify data [corrected] with poor fits to a mathematical discounting model as nonsystematic data to be eliminated [corrected] DataExpand
  • 304
  • 23
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
RationaleThis dose-effect study extends previous observations showing that psilocybin can occasion mystical-type experiences having persisting positive effects on attitudes, mood, andExpand
  • 339
  • 23
  • PDF
The Sexual Discounting Task: HIV risk behavior and the discounting of delayed sexual rewards in cocaine dependence.
BACKGROUND Cocaine dependence is associated with high rates of sexual risk behavior and HIV infection. However, little is known about the responsible mechanism(s). METHODS Cocaine-dependentExpand
  • 115
  • 17
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.
Hypnotic drugs, including benzodiazepine receptor ligands, barbiturates, antihistamines, and melatonin receptor ligands, are useful in treating insomnia, but clinicians should consider the relativeExpand
  • 192
  • 15
Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The ratedExpand
  • 95
  • 15
  • PDF
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.
A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few scientific studies have attempted to measure orExpand
  • 125
  • 14
  • PDF
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences
Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an onlineExpand
  • 85
  • 12
  • PDF
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety andExpand
  • 268
  • 11
  • PDF